When multiple myeloma relapses

RESPOND with higher response rates with Kyprolis®-based regimens (vs Vd)

Kd overall response rate

In the ENDEAVOR trial, more than half of patients achieved at least VGPR with Kd.1

Adapted from Dimopoulos et al.1

Kyprolis®-based regimens consistently provided benefit to relapsed multiple myeloma patients, across different measures of response1

Kyprolis® has a tolerable safety profile in combination with dexamethasone

*Descriptive P value.

Please read the SmPC for full comprehensive safety information


  1. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.

Terms of Use

The information contained in this site is for European healthcare professionals only.